December 19, 2016December 19, 2016

Arena Completes Enrollment in Phase 2 Trial of PAH Therapy Ralinepag

Arena Pharmaceuticals completed patient enrollment in its Phase 2 clinical trial evaluating ralinepag (APD811) for the treatment of pulmonary arterial hypertension (PAH). The clinical trial (NCT02279160) first began dosing patients in ... Read more

January 16, 2015November 5, 2015

Arena to Initiate Dosing on Phase 2 PAH Therapy Study

News, Pulmonary Hypertension

Arena Pharmaceuticals, Inc. has announced that it will initiate dosing of the first patients in its phase 2 clinical trial for the evaluation of a potential therapy for pulmonary arterial hypertension (PAH), called ralinepag. ... Read more